A Phase II Pilot Study of Anti‐ PD ‐ L1 , Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation is a research paper published in Cancer Medicine (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →Intramural NIH HHS
Grant: ZIA BC011525
AstraZeneca Durvalumab and olaparib were supplied to the NCI/C
AstraZeneca
MeSH Terms
Keywords